

## Part II

### Summary of Product Characteristics

#### 1 NAME OF THE MEDICINAL PRODUCT

Allopurinol 300 mg Tablets BP.

#### 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains 300 mg Allopurinol.

Excipients: Each tablet contains 175 mg of lactose as lactose monohydrate.

For a full list of excipients, see section 6.1.

#### 3 PHARMACEUTICAL FORM

Tablet.

Round, biconvex, white tablets with a breakline and “ALL 300” on one side and a twin triangle logo on reverse.

#### 4 CLINICAL PARTICULARS

##### 4.1 Therapeutic Indications

Allopurinol is indicated for reducing urate/uric acid formation in conditions where urate/uric acid deposition has already occurred (e.g. gouty arthritis, skin tophi, nephrolithiasis) or is a predictable clinical risk (e.g. treatment of malignancy potentially leading to acute uric acid nephropathy).

The main clinical conditions where urate/uric acid deposition may occur are:

- Idiopathic gout;
- Uric acid lithiasis;
- Acute uric acid nephropathy;
- Neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously, or after cytotoxic therapy;
- Certain enzyme disorders which lead to overproduction of urate, for example;
  - hypoxanthine-guanine phosphoribosyltransferase, including Lesch-Nyhan syndrome;
  - glucose-6-phosphatase including glycogen storage disease;
  - phosphoribosylpyrophosphate synthetase;
  - phosphoribosylpyrophosphate amidotransferase;
  - adenine phosphoribosyltransferase;

Allopurinol is indicated for the management of 2, 8-dihydroxyadenine (2, 8-DHA) renal stones related to deficient activity of adenine phosphoribosyltransferase.

Allopurinol is indicated for the management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricoosuria, when fluid, dietary and similar measures have failed.

## 4.2 Posology and method of administration

### **Adults:-**

Allopurinol should be introduced at low dosage e.g. 100mg/day to reduce the risk of adverse reactions and increased only if the serum urate response is unsatisfactory. Extra caution should be exercised if renal function is poor (see *Dosage in renal impairment*). The following dosage schedules are suggested:

100 to 200mg daily in mild conditions,  
300 to 600mg daily in moderately severe conditions,  
700 to 900mg daily in severe conditions.

Dosage higher than 300mg should be given in divided doses not exceeding 300mg at any time. If dosage on a mg/kg bodyweight basis is required, 2 to 10mg/kg bodyweight/day should be used. Where available, Zyloric granules should be used in preference to the halving of tablets.

### **Children:-**

Under 15 years of age: 10 to 20mg/kg body weight up to a maximum of 400mg. Use is mainly in malignant conditions or enzyme disorders such as Lesch-Nyhan syndrome.

### **Elderly:-**

In the absence of specific data, the lowest dosage which produces satisfactory urate reduction should be used. Particular attention should be paid to advice in (*Dosage in renal impairment* and *Special Warnings and Precautions for Use*).

### **Renal impairment:-**

Since allopurinol and its metabolites are excreted by the kidney, impaired renal function may lead to retention of the drug and/or its metabolites with consequent prolongation of plasma half-lives. In severe renal insufficiency, it may be advisable to use less than 100mg per day or to use single doses of 100mg at longer intervals than one day.

If facilities are available to monitor plasma oxipurinol concentrations, the dose should be adjusted to maintain plasma oxipurinol levels below 100µmol/litre (15.2mg/litre).

Allopurinol and its metabolites are removed by renal dialysis. If dialysis is required two to three times a week consideration should be given to an alternative dosage schedule of 300-400mg Allopurinol immediately after each dialysis with none in the interim.

### **Dosage in hepatic impairment:-**

Reduced doses should be used in patients with hepatic impairment. Periodic liver function tests are recommended during the early stages of therapy.

### **Treatment of high urate turnover conditions, e.g. neoplasia, Lesch-Nyhan syndrome:-**

It is advisable to correct existing hyperuricaemia and/or hyperuricosuria with Allopurinol before starting cytotoxic therapy. It is important to ensure adequate hydration to maintain optimum diuresis and to attempt alkalinisation of urine to increase solubility of urinary urate/uric acid. Dosage of Allopurinol should be at the lower end of the recommended dosage schedule.

If urate nephropathy or other pathology has compromised renal function, the advice given in *Dosage in renal impairment* should be followed.

These steps may reduce the risk of xanthine and/or oxipurinol deposition complicating the clinical situation.

### **Monitoring Advice**

The dosage should be adjusted by monitoring serum urate concentrations and urinary urate/uric acid levels at appropriate intervals.

**Instructions for Use**

Allopurinol may be taken orally once a day after a meal. It is well tolerated, especially after food. Should the daily dosage exceed 300mg and gastrointestinal intolerance be manifested, a divided dose regimen may be appropriate.

**Route of Administration**

Oral.

**4.3 Contraindications**

Use in patients hypersensitive to allopurinol.

Use in patients who are breast feeding infants.

Use in acute gout.

Use in patients who are allergic to the excipients present in this medicinal product.

**4.4 Special warnings and precautions for use**

Allopurinol should be withdrawn **immediately** if a skin rash or other evidence of sensitivity occurs. Skin reactions may be pruritic, maculopapular, sometimes scaly or purpuric and rarely exfoliative. Allopurinol should be withdrawn immediately and permanently at the first sign of intolerance.

Reduced doses should be used in patients with hepatic or renal impairment. Patients under treatment for hypertension or cardiac insufficiency, for example with diuretics or ACE inhibitors, may have some concomitant impairment of renal function and allopurinol should be used with care in this group.

Asymptomatic hyperuricaemia is generally not considered an indication for use of Allopurinol. Fluid and dietary modification with management of the underlying cause may correct the condition.

**Acute gouty attacks:-**

Allopurinol treatment should not be started until an acute attack of gout has completely subsided, as further attacks may be precipitated.

In the early stages of treatment with Allopurinol, as with uricosuric agents, an acute attack of gouty arthritis may be precipitated. Therefore it is advisable to give a prophylactic dose with a suitable anti-inflammatory agent or colchicines for at least one month. The literature should be consulted for details of appropriate dosage and precautions and warnings.

If acute attacks develop in patients receiving allopurinol, treatment should continue at the same dosage while the acute attack is treated with a suitable anti-inflammatory agent.

**Xanthine deposition;-**

In conditions where the rate of urate formation is greatly increased (e.g. Malignant disease and its treatment, Lesch-Nyhan syndrome), the absolute concentration of xanthine in urine could, in rare cases, rise sufficiently to allow deposition in the urinary tract. This risk may be minimised by adequate hydration to achieve optimal dilution.

**Impaction of uric acid renal stones;-**

Adequate therapy with Allopurinol will lead to dissolution of large uric acid renal pelvic stones with the remote possibility of impaction in the ureter.

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

## 4.5 Interaction with other medicinal products and other forms of interaction

### *6-mercaptopurine and azathioprine*

Allopurinol inhibits the metabolism of 6-mercaptopurine or azathioprine when given concurrently. The dose of 6-mercaptopurine and azathioprine should be reduced to one-quarter of the usual dose.

### *Vidarabine (Adenine Arabinoside)*

Evidence suggests that the plasma half-life of vidarabine is increased in the presence of allopurinol. When the two products are used concomitantly extra vigilance is necessary, to recognise enhanced toxic effects.

### *Salicylates and uricosuric agents*

Concurrent administration with uricosurics including probenecid and salicylates may lead to an increased rate of excretion of oxipurinol. This may decrease the therapeutic activity of Allopurinol therefore, dosage may require adjustment.

### *Chlorpropanamide*

If Allopurinol is given concomitantly with chlorpropamide when renal function is poor, there may be an increased risk of prolonged hypoglycaemic activity because allopurinol and chlorpropamide may compete for excretion in the renal tubule.

### *Coumarin anticoagulants*

There have been rare reports of increased effect of warfarin and other coumarin anticoagulants when co-administered with allopurinol, therefore, all patients receiving anticoagulants must be carefully monitored.

### *Phenytoin*

Allopurinol may inhibit hepatic oxidation of phenytoin but the clinical significance has not been demonstrated.

### *Theophylline*

Inhibition of the metabolism of theophylline has been reported. The mechanism of the interaction may be explained by xanthine oxidase being involved in the biotransformation of theophylline in man. Theophylline levels should be monitored in patients starting or increasing allopurinol therapy.

### *Ampicillin/Amoxicillin*

An increase in the frequency of skin rashes has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs. The cause of the reported association has not been established. However, it is recommended that in patients receiving allopurinol an alternative to ampicillin or amoxicillin is used where available.

### *Cyclophosphamide, doxorubicin, bleomycin, procarbazine, mechloroethamine*

Enhance bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease (other than leukaemia), in the presence of allopurinol. However in a well-controlled study of patients treated with cyclophosphamide, doxorubicin, bleomycin, procarbazine and/or mechloroethamine (mustine hydrochloride) allopurinol did not appear to increase the toxic reaction of these cytotoxic agents.

### *Cyclosporin*

Reports suggest that the plasma concentration of cyclosporine may be increased during concomitant treatment with allopurinol. The possibility of enhanced cyclosporine toxicity should be considered if the drugs are co-administered.

### *Didanosine*

In healthy volunteers and HIV patients receiving didanosine, plasma didanosine C<sub>max</sub> and AUC values were approximately doubled with concomitant allopurinol treatment (300mg daily) without affecting terminal half life. Therefore, dose reductions of didanosine may be required when used concomitantly with allopurinol.

## 4.6 Pregnancy and lactation

Allopurinol should not be used during pregnancy unless considered essential by the physician.

Allopurinol and its metabolites were demonstrated to be in the breast milk of an individual studied after a single dose of allopurinol. There are no data concerning the effect of these metabolites on the breast-fed baby.

## 4.7 Effects on ability to drive and use machines

Since adverse reactions such as somnolence, vertigo and ataxia have been reported in patients receiving allopurinol, patients should exercise caution before driving, using machinery or participating in dangerous activities until they are reasonably certain that allopurinol does not adversely affect performances.

## 4.8 Undesirable effects

### Skin and hypersensitivity reactions

Skin reactions are the most common adverse effect, and may occur at any time during treatment. They may be pruritic, maculopapular, sometimes scaly or pruritic and rarely exfoliative.

Allopurinol should be withdrawn immediately should such reactions occur.

After recovery from mild skin reactions, allopurinol may be re-introduced at low dose (e.g. 50 mg/day); this may be gradually increased.

If the rash recurs, allopurinol should be withdrawn immediately and permanently.

Skin reactions associated with exfoliation, fever, lymphadenopathy, arthralgia and eosinophilia resembling Stevens-Johnson and/or Lyell's syndrome occur rarely. Associated vasculitis and tissue response may be manifested in various ways including hepatitis, interstitial nephritis and, very rarely, epilepsy. If such reactions do occur allopurinol should be withdrawn immediately and permanently.

Corticosteroids may be beneficial in treating such reactions. When generalised hypersensitivity reactions have occurred, hepatic and/or renal disorder has usually been present particularly when the outcome has been fatal.

Very rarely acute anaphylactic shock has been reported.

### Angioimmunoblastic lymphadenopathy

Angioimmunoblastic lymphadenopathy has been described rarely following biopsy of a generalised lymphadenopathy. It appears to be reversible on withdrawal of allopurinol.

### Hepatic function

Rare cases of hepatic dysfunction ranging from asymptomatic rises in liver function tests to hepatitis (including hepatic necrosis and granulomatous hepatitis) have been reported without overt evidence of more generalised hypersensitivity.

### Gastrointestinal disorder

Nausea and vomiting can largely be avoided by taking allopurinol after meals.

Recurrent haematemesis has been reported as an extremely rare event, as has steatorrhoea.

### Blood and lymphatic system

There have been occasional reports of thrombocytopenia, agranulocytosis and aplastic anaemia, usually in association with impaired renal and/or hepatic function.

**Miscellaneous**

The following complaints have been reported occasionally: fever, general malaise, asthenia, headache, vertigo, ataxia, somnolence, coma, depression, paralysis, paraesthesiae, neuropathy, visual disorders, cataracts, macular changes, taste perversion, stomatitis, changed bowel habit, infertility, impotence, diabetes mellitus, hyperlipidaemia, furunculosis, alopecia, discoloured hair, angina, hypertension, bradycardia, oedema, uraemia, haematuria, angioedema and gynaecomastia.

**4.9 Overdose**

Accidental or deliberate ingestion of up to 22.5g allopurinol without adverse effect has been reported. Symptoms and signs including nausea, vomiting, diarrhoea and dizziness have been reported in a patient who ingested 20g allopurinol. Recovery followed general supportive measures.

The most likely reaction would be gastrointestinal intolerance. Massive absorption of allopurinol may lead to considerable inhibition of xanthine oxidase activity which should have no untoward effects unless 6-mercaptopurine, adenine arabinoside, and/or azathioprine is being taken concomitantly.

In these cases the risk of increased activity of these drugs must be recognised. Adequate hydration to maintain optimum diuresis facilitates excretion of allopurinol and its metabolites. Dialysis may be resorted to if considered necessary.

**5 PHARMACOLOGICAL PROPERTIES****5.1 Pharmacodynamic properties**

Allopurinol is a xanthine oxidase inhibitor which reduces the oxidation of hypoxanthine to xanthine and xanthine to uric acid. In addition to the inhibition of purine catabolism, in some but not all hyperuricaemic patients, de novo purine biosynthesis is depressed via feedback inhibition of hypoxanthine-guanine phosphoribosyltransferase. Other metabolites of allopurinol include allopurinol-riboside and oxipurinol-7-riboside.

**5.2 Pharmacokinetic properties**

Allopurinol is active when given orally and is rapidly absorbed from the upper gastrointestinal tract. Studies have detected allopurinol in the blood 30-60 minutes after dosing. Estimates of bioavailability vary from 67% to 90%. Peak plasma levels of allopurinol generally occur approximately 1.5 hours after oral administration of allopurinol, but fall rapidly and are barely detectable after 6 hours. Peak plasma levels of oxipurinol generally occur after 3-5 hours after oral administration of allopurinol and are much more sustained.

Allopurinol is negligibly bound by plasma proteins and therefore variation in protein binding are not thought to significantly alter clearance. The apparent volume of distribution of allopurinol is approximately 1.6 litre/Kg which suggests relatively extensive uptake by tissues. Tissue concentrations of allopurinol have not been reported in humans, but it is likely that allopurinol and oxipurinol will be present in the highest concentrations in the liver and intestinal mucosa where xanthine oxidase activity is high.

Approximately 20% of the ingested allopurinol is excreted in the faeces. Elimination of allopurinol is mainly by metabolic conversion to oxipurinol by xanthine oxidase and aldehyde oxidase, with less than 10% of the unchanged drug excreted in the urine. Allopurinol has a plasma half-life of about 1 to 2 hours.

Oxipurinol is a less potent inhibitor of xanthine oxidase than allopurinol, but the plasma half-life of oxipurinol is far more prolonged. Estimates range from 13 to 30 hours in man. Therefore effective inhibition of xanthine oxidase is maintained over a 24 hour period with a single daily dose of allopurinol. Patients with normal renal function will gradually accumulate oxipurinol until a steady-state plasma oxipurinol concentration is reached.

Such patients taking 300mg of allopurinol per day will generally have plasma oxipurinol concentrations of 5-10mg/litre.

Oxipurinol is eliminated unchanged in the urine but has a long elimination half-life because it undergoes tubular reabsorption. Reported values for the elimination half-life from 13.6 hours to 29hours. The large discrepancies in these values may be accounted for by variation in study design and/or creatinine clearance in the patients.

#### *Pharmacokinetics in patients with renal impairment*

Allopurinol and oxipurinol clearance is greatly reduced in patients with poor renal function resulting in higher plasma levels in chronic therapy. Patients with renal impairment, where creatinine clearance values were between 10 and 20ml/min, showed plasma oxipurinol concentrations of approximately 30mg/litre after prolonged treatment with 300mg allopurinol per day. This is approximately the concentration which would be achieved by doses of 600mg/day in those with normal renal function. A reduction in the dose of allopurinol is therefore required in patients with renal impairment.

#### *Pharmacokinetics in elderly patients*

The kinetics of the drug are not likely to be altered other than due to deterioration in renal function (see *Pharmacokinetics in patients with renal impairment*).

### **5.3 Preclinical safety data**

#### *Mutagenicity*

Cytogenetic studies show that allopurinol does not induce chromosome aberrations in human blood cells *in vitro* at concentrations up to 100µg/ml and *in vivo* at doses up to 600mg/day for a mean period of 40 months.

Allopurinol does not produce nitroso compounds *in vitro* or affect lymphocyte transformation *in vitro*.

Evidence from biochemical and other cytological investigations strongly suggests that allopurinol has no deleterious effects on DNA at any stage of the cell cycle and is not mutagenic.

#### *Carcinogenicity*

No evidence of carcinogenicity has been found in mice and rats treated with allopurinol for up to 2 years.

#### *Teratogenicity*

One study in mice receiving intraperitoneal doses of 50 or 100mg/kg on days 10 or 13 of gestation resulted in foetal abnormalities, however in a similar study in rats at 120mg/kg on day 12 of gestation no abnormalities were observed. Extensive studies of high oral doses of allopurinol in mice up to 100mg/kg/day, rats up to 200mg/kg/day and rabbits up to 150mg/kg/day during days 8 to 16 of the gestation produced no teratogenic effects.

An *in vitro* study using foetal mouse salivary glands in culture to detect embryotoxicity without also causing maternal toxicity.

## **6 PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Lactose monohydrate  
Maize starch  
Pregelatinised maize starch 1500  
Sodium starch glycolate (Type A)  
Colloidal anhydrous silica  
Magnesium stearate  
Povidone K30

### **6.2 Incompatibilities**

Not applicable.

### **6.3 Shelf Life**

5 years.

### **6.4 Special precautions for storage**

Do not store above 25<sup>0</sup>C. Keep tablet container tightly closed.

### **6.5 Nature and contents of container**

Polypropylene containers with tamper-evident polyethylene closures. Each container is of a suitable size to hold 50, 100, 250, 500 and 1000 tablets.

Not all pack sizes may be marketed.

### **6.6 Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product**

No special requirements.

## **7 MARKETING AUTHORISATION HOLDER**

Norton Healthcare Limited  
Albert Basin  
Royal Docks  
London  
E16 2QJ  
United Kingdom

## **8 MARKETING AUTHORISATION NUMBER**

PA 0282/021/002

## **9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorization: 01 December 1982

Date of last renewal: 01 December 2007

## **10 DATE OF REVISION OF THE TEXT**

July 2008